Global gynecology drugs market was valued over USD14139 million in 2021 and is anticipated to grow at CAGR of 8.64% through 2027. Changing lifestyle choices are contributing to the increased gynecological disorders and thereby driving the gynecology drugs market through 2027.
The increasing awareness among the female population regarding various gynecological illnesses and their long-term effects is supporting the growth of the market. As a result of increased demand, major players in the gynecological drugs market are becoming increasingly interested in expanding their product offerings and distribution networks. These efforts point to a potential expansion of the worldwide gynecological drugs market from 2017 to 2027.
Global gynecology drug market is segregated based on therapeutics, indication, distribution channel and others. Based on therapeutics, market is bifurcated into Non-Hormonal Therapy vs Hormonal Therapy. In terms of indication, market is segregated into Contraception, Gynecology infections, Female infertility, Postmenopausal Disorders, Polycystic Ovary Syndrome, Gynecology Cancer, Endometriosis. By distribution channel, market is segmented into Retail Pharmacies, Hospital Pharmacies Online Pharmacies. Online Pharmacies accounted for share of 22.49% in 2021 and this segment is predicted to grow at the fastest CAGR of 9.11% among all pharmacy distribution channels across the world. The outbreak of COVID-19 accelerated the trend of digitalization in healthcare industry, which majorly includes the access to telemedicine, eHealth platforms as well as online prescription and growth in OTC drugs.
Leading companies operating in the gynecology drug market include Amgen Inc., F. Hoffmann La Roche Ltd., Novartis AG, Bayer AG, Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, AstraZeneca Plc, Lupin Limited, Johnson and Johnson, Sanofi SA, Ferring Pharmaceuticals among others.